Aldeyra Therapeutics, Inc. (ALDX): R&D Expense
$25.66M
Year ended 2025-12-31
$15.63M
Trailing 12 months to 2026-06-30
-18.4%
3-year compound annual growth
+0.8%
5-year compound annual growth
+13.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.66M | -46.8% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $48.22M | +63.7% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $29.46M | -37.7% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $47.31M | +5.3% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $44.94M | +82.1% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $24.68M | -44.4% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $44.35M | +48.7% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $29.82M | +82.9% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $16.30M | +23.7% | 2019-03-08, From 2017-01-01 |
| 2016-12-31 | $13.18M | +74.0% | 2018-03-29, From 2016-01-02 |
| 2015-12-31 | $7.57M | +104.3% | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | $3.71M | +140.5% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $1.54M | n/a | 2015-03-23, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $25.66M | -46.8% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $33.72M | +73.9% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.83M | -20.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $31.86M | +40.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.40M | -74.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $22.03M | -23.4% |
Compare ALDX, CRVS, INO, HOWL side by side · Screen every company in Pharmaceutical Preparations ↗